DR. SATHISHKUMAR KURUSAMY
With PhD in Molecular Medicine and expertise in signalling mechanisms that regulate angiogenesis in different disease conditions, Dr. Kurusamy works on the preclinical development of our proprietary formulations of Disulfiram.
Gowtham has an incredible dedication to our work and as a recent addition to the team, he is working on translating Disulfiram and its metabolites for the treatment of Multiple Myeloma. His work is in direct collaboration with clinical network from Wolverhampton New cross hospital and Midlands NHS clinical network.
Research and Innovation Graduate
With MRes degree in Translational medicine, Ben is responsible for bridging the academic and commercial side of Disulfican. Ben's work on translation of Disulfiram and its derivatives for Pancreatic Cancer is sponsored by Science in Research and Industry Centre (SIRC) as a part of ERDF development scheme.
As a previous international research exchange student working in the group, Samna has returned as a full time MPhil research student to work on our Glioblastoma project contributing to the orphan drug development strategy of Disulfican.
Karim is a final year PhD student who works on understanding the molecular mechanisms behind chemoresistance in Glioblastoma and reversing it using Disulfiram. Particularly his focus has been on using Disulfiram to suppress the local invasion and infiltration of this aggressive brain tumour.
Ogechi is a final year PhD student working on investigating the molecular mechanisms of Disulfiram in targeting the drug resistant cancer stem cell population in Pancreatic Cancer. Mainly she focuses on testing Disulfiram on a panel of primary patient derived pancreatic cancer cells with different mutational and clinical characteristics collected from primary pancreatic site, in circulation and from metastatic sites.
Garima's work focuses on testing the PLGA-encapsulated Disulfiram microparticles on malignant mesothelioma cell lines. Her work has generated key proof of concept data using pre-GMP version of PLGA-Disulfiram before scaling up to GMP production in Disulfican's innovate UK project for commercialisation.
Kate's work focussed on translation of PLGA-encapsulated Disulfiram for treatment of non-small cell lung cancer which is the leading cause of cancer deaths in the World. Her work also throws light on combination strategies for using Disulfiram with currently used first line NSCLC drugs.